Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases: REVIEW

British Journal of Pharmacology

Volumn 159, Issue 3, 2010, Pages 502-517

  Siller Matula, Jolanta M ^a   Krumphuber, Julia ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ARC1779; BX 667; Cangrelor; E5555; Elinogrel; Prasugrel; SCH 530348; SCH 602539; Terutroban; Ticagrelor

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; AJW 200; ALX 0081; ANTITHROMBOCYTIC AGENT; APTAMER; ARC 1779; BX 048; BX 667; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450; E 5555; ELINOGREL; HEPARIN; HIRULOG; IMMUNOGLOBULIN G4; PRASUGREL; PROTEIN INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 1; PRT 060128; PURINERGIC RECEPTOR BLOCKING AGENT; SCH 205831; SCH 602539; TERUTROBAN; TICAGRELOR; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; AREA UNDER THE CURVE; BINDING SITE; BLEEDING; BLOOD LEVEL; BRADYCARDIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISTRIBUTION VOLUME; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DYSPNEA; ELECTIVE SURGERY; GASTROINTESTINAL HEMORRHAGE; GOLD STANDARD; HEADACHE; HEART CATHETERIZATION; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEMATURIA; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTHROMBIN TIME; RENAL PROTECTION; REVASCULARIZATION; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; STENT; STENT THROMBOSIS; STROKE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VASCULAR DISEASE; VASCULAR PATENCY;

ADENOSINE; ADENOSINE MONOPHOSPHATE; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; HUMANS; LACTONES; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; RECEPTORS, PROTEINASE-ACTIVATED; THIOPHENES; TICLOPIDINE; VON WILLEBRAND FACTOR;

EID: 76549094772     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00555.x     Document Type: Review

References (90)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2 S1 209.
2. Andre P, Jurek M, Sim D, Deguzman F, Hollenbach S, Phillips DR et al. (2007). PRT060128, a novel, direct-acting orally available P2Y12 antagonist, confers superior antithrombotic activity over clopidogrel in a mice thrombosis model. J Thromb Haemost 5 : O-W-031.
3. Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK (2009). Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 103 : 40A 51A.
4. Barrett NE, Holbrook L, Jones S, Kaiser WJ, Moraes LA, Rana R et al. (2008). Future innovations in anti-platelet therapies. Br J Pharmacol 154 : 918 939.
5. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A et al. (2009). Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373 : 919 928.
6. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS et al. (2007). A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153 : 66 e9-16.
7. Bryant J, Post JM, Alexander S, Wang YX, Kent L, Schirm S et al. (2008). Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets. Thromb Res 122 : 523 532.
8. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G et al. (2007). Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50 : 1844 1851.
9. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS et al. (2008). Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 51 : 3061 3064.
10. Chamorro A (2009). TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 27 (Suppl. 3 20 27.
11. Chintala M, Ahn H, Foster C, Xia Y, Chackalamannil S (2005a). Antithrombotic effects of SCH 205831: a potent, selective and orally active antagonist of the PAR-1 thrombin receptor. J Thromb Haemost 3 : Abstract OR286.
12. Chintala M, Ahn HS, Foster C, Xia Y, Chackalamannil S (2005b). Chintala M, Ahn HS, Foster C, Xia Y, Chackalamannil S. J Thromb Haemost 3 (Suppl. OR286.
13. Chintala M, Kurowski S, Vemulapalli S, Li Q, Brown A, Strony J (2007). Efficacy of SCH 602539, a selective thrombin receptor antagonist alone and in combination with cangrelor in a Folts model of thrombosis in nesthetized monkeys. Eur Heart J 28 (Suppl. 1 188.
14. Chintala M, Shimizu K, Ogawa M, Yamaguchi H, Doi M, Jensen P (2008). Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci 108 : 433 438.
15. Diener JL, Daniel Lagasse HA, Duerschmied D, Merhi Y, Tanguay JF, Hutabarat R et al. (2009). Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 7 : 1155 1162.
16. Doggrell SA (2009). Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes. IDrugs 12 : 309 317.
17. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S (2008). The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 6 : 1153 1159.
18. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS, 2nd., Brandt JT et al. (2007a). Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81 : 735 741.
19. Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A et al. (2007b). The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 35 : 1096 1104.
20. Farid NA, Payne CD, Ernest CS, 2nd., Li YG, Winters KJ, Salazar DE et al. (2008). Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol 48 : 53 59.
21. Firbas C, Jilma B, Gilbert JC, Schranz S, Knöbl P (2009). The anti von Willebrand factor aptamer ARC1779 increases platelet counts in a patient with familial thrombotic thrombocytopenic purpura (TTP). J Thromb Haemost 7 (Suppl. 1 OC-WE-011.
22. Gaussem P, Reny JL, Thalamas C, Chatelain N, Kroumova M, Jude B et al. (2005). The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 3 : 1437 1445.
23. van Gestel MA, Heemskerk JW, Slaaf DW, Heijnen VV, Reneman RS, oude Egbrink MG (2003). In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol 23 : 518 523.
24. van Giezen JJ, Humphries RG (2005). Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 31 : 195 204.
25. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN et al. (2007). First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116 : 2678 2686.
26. Goto S, Yamaguchi T, Ikeda Y, Yamaguchi H, Shimizu K, Jensen P (2008). Phase II trial of the novel antiplatelet agent, SCH 530348, in Japanese patients with non-ST segment elevation acute coronary syndromes (NSTE ACS). Eur Heart J 29 (Suppl.): Abstract: P4767.
27. Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC et al. (2006). Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 151 : 689. e1 689. e10.
28. Greenbaum AB, Ohman EM, Gibson CM, Borzak S, Stebbins AL, Lu M et al. (2007). Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J 154 : 702 709.
29. Gurbel PA, Conley PB, Andre P, Stephens G, Gretler DD, Jurek MM et al. (2008). Oral Dosing of PRT060128, a Novel Direct-acting, Reversible P2Y12 Antagonist Overcomes High Platelet Reactivity in Patients Non-responsive to Clopidogrel Therapy. Circulation 118 : S-972.
30. Hennerici MG (2009). Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study. Cerebrovasc Dis 27 (Suppl. 3 28 32.
31. Holz J, Bartunek J, Barbato E, Vercruysse K, Pullan S, Heyndrickxs G (2009). ALX-0081 a novel anti-thrombotic: first results of a multiple dose phase 1 study in patients with stable angina undergoing PCI. J Thromb Haemost (Suppl. abstract PP-WE-416.
32. Hong TT, Huang J, Driscoll E, Lucchesi BR (2006). Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis. J Cardiovasc Pharmacol 48 : 239 248.
33. Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR (2000). Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J Pharmacol Exp Ther 295 : 492 499.
34. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G (2006). Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27 : 1038 1047.
35. Hutchaleelaha A, Ye C, Lambing JL, Desai M, Gu ZM, Kissling J et al. (2008). Metabolism and excretion of PRT060128, a new direct-acting, reversible P2Y12 inhibitor, in healthy human subjects. AAPS J http://www.aapsj.org/ abstracts/AM-2008/AAPS2008-001676.PDF
36. Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI et al. (1999). Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 42 : 213 220.
37. Jacobsson F, Swahn E, Wallentin L, Ellborg M (2002). Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 24 : 752 765.
38. Jakubowski JA, Matsushima N, Asai F, Naganuma H, Brandt JT, Hirota T et al. (2007a). A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 63 : 421 430.
39. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L (2007b). Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 25 : 357 374.
40. Jilma B, Jilma P, Gilbert JC, Hutabarat R, Siller J, Spiel A et al. (2009). Safety, pharmacokinetics and pharmacodynamics of the anti von Willebrand factor aptamer ARC1779 in patients with acute thrombotic thrombocytopenic purpura TTP. J Thromb Haemost 7 (Suppl. 1 AS-WE-014.
41. Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF (2008). The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 19 : 125 133.
42. Kageyama S, Yamamoto H, Nakazawa H, Matsushita J, Kouyama T, Gonsho A et al. (2002). Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol 22 : 187 192. (Pubitemid 34076252)
43. Kasoglou T, Reyderman L, Robert R (2005). Pharmacodynamics and pharmacocinetics of a novel protease-activated receptor (PAR-1) antagonist SCH 530348. Circulation 112 : 1132.
44. Knobl P, Jilma B, Gilbert JC, Hutabarat RM, Wagner PG, Jilma-Stohlawetz P (2009). Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion doi: 10.1111/j.1537-2995.2009.02232.x.
45. Kogushi M, Yokohama H, Kitamura S, Hishinuma I (2007). Effects of E5555, a protease-activated receptor-1 antagonist, on the inflammatory markers in vitro. J Thromb Haemost 5 : Abstract: P-M-059.
46. Li YG, Ni L, Brandt JT, Small DS, Payne CD, Ernest CS et al. (2009). Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets 20 : 316 327.
47. McNicol A, Israels SJ (2003). Platelets and anti-platelet therapy. J Pharmacol Sci 93 : 381 396.
48. Michelson AD (2009). New P2Y12 antagonists. Curr Opin Hematol 16 : 371 377.
49. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH et al. (2009). Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373 : 723 731.
50. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K et al. (2008). Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 29 : 2473 2479.
51. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F (2005). Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 31 : 184 194.
52. Paulinska P, Spiel A, Jilma B (2009). Role of von Willebrand factor in vascular disease. Hamostaseologie 29 : 32 38.
53. Payne CD, Li YG, Small DS, Ernest CS, 2nd., Farid NA, Jakubowski JA et al. (2007). Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 50 : 555 562.
54. Pitchford SC (2007). Novel uses for anti-platelet agents as anti-inflammatory drugs. Br J Pharmacol 152 : 987 1002.
55. Post JM, Alexander S, Wang YX, Vincelette J, Vergona R, Kent L et al. (2008). Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res 122 : 533 540.
56. Raju NC, Eikelboom JW, Hirsh J (2008). Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med 5 : 766 780.
57. Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A et al. (2006). Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34 : 600 607.
58. Schomig A (2009). Ticagrelor - is there need for a new player in the antiplatelet-therapy field? N Engl J Med 361 : 1108 1111.
59. Schranz S, Jilma B, Firbas C, Gilbert JC, Hutabarat R, Knöbl P (2009). Pharmacokinetics and pharmacodynamics of the aptamer ARC1779, a specific inhibitor of von Willebrand factor A1 domains. A pilot study in patients with type 2B von Willebrand disease. J Thromb Haemost 7 (Suppl. 1 PP-MO-622.
60. Sebekova K, Eifert T, Klassen A, Heidland A, Amann K (2007). Renal effects of S18886 (Terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes. Diabetes 56 : 968 974.
61. Sebekova K, Ramuscak A, Boor P, Heidland A, Amann K (2008). The selective TP receptor antagonist, S18886 (terutroban), attenuates renal damage in the double transgenic rat model of hypertension. Am J Nephrol 28 : 47 53.
62. Serebruany V, Shalito I, Kopyleva O (2009a). Prasugrel development - claims and achievements. Thromb Haemost 101 : 14 22.
63. Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL (2009b). The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 102 : 111 119.
64. Shinohara Y, Goto S, Shimizu K, Jensen P, Shinohara Y, Goto S et al. (2008). A phase II safety study of novel antiplatelet agent, SCH 530348, in Japanese patients with prior ischemic stroke. Int J Stroke 3 (Suppl. 1 Abstract PO01-193.
65. Siller-Matula J, Schror K, Wojta J, Huber K (2007). Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 97 : 385 393.
66. Siller-Matula JM, Lang I, Christ G, Jilma B (2008). Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52 : 1557 1563.
67. Siller-Matula JM, Gouya G, Wolzt M, Jilma B (2009a). Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 102 : 397 403.
68. Siller-Matula JM, Haberl K, Prillinger K, Panzer S, Lang I, Jilma B. (2009b). The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res 123 : 874 880.
69. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B (2009c). Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157 : 148 e1-5.
70. Spiel AO, Gilbert JC, Jilma B (2008). von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 117 : 1449 1459.
71. Spiel AO, Mayr FB, Ladani N, Wagner PG, Schaub RG, Gilbert JC et al. (2009). The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets 20 : 334 340.
72. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS (2008). Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121 : 527 534.
73. Storey RF, Oldroyd KG, Wilcox RG (2001). Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85 : 401 407.
74. Storey RF, Wilcox RG, Heptinstall S (2002). Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 13 : 407 413.
75. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G et al. (2007). Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50 : 1852 1856.
76. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H (2000). The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 129 : 1439 1446.
77. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M et al. (2007). The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 5 : 1545 1551.
78. Tantry US, Bliden KP, Gurbel PA (2007). Azd6140. Expert Opin Investig Drugs 16 : 225 229.
79. Ulrichts H, Schoolmeester A, Hoefman S, Lauwereys M, Casteels P, Stanssens P et al. (2009). Anti-thrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to current marketed antiplatelet drugs. J Thromb Haemost (Suppl. abstract AS-TH-024.
80. Vilahur G, Casani L, Badimon L (2007). A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost 98 : 662 669.
81. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA et al. (2008). Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 : 21 30.
82. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 : 1045 1057.
83. Wang K, Zhou X, Zhou Z, Tarakji K, Carneiro M, Penn MS et al. (2003). Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol 23 : 357 362.
84. Wang YX, Vincelette J, da Cunha V, Martin-McNulty B, Mallari C, Fitch RM et al. (2007). A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb Haemost 97 : 847 855.
85. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD et al. (2005). Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111 : 3366 3373.
86. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. (2007a). Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 : 2001 2015. (Pubitemid 350106708)
87. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD et al. (2007b). Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 : 2923 2932.
88. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW et al. (2008). Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118 : 1626 1636.
89. Wong PC, Crain EJ, Watson CA, Hua J, Schumacher WA, Rehfuss R (2009). Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thromb Haemost 101 : 108 115.
90. Xu S, Jiang B, Maitland KA, Bayat H, Gu J, Nadler JL et al. (2006). The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 55 : 110 119.